Citadel Advisors’s Rallybio RLYB Stock Holding History

Citadel Advisors’s Portfolio RLYB Stock Details RLYB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.16M	Buy	72,200 +52,314	+263%	+$673K	﹤0.01%	7857
2026 Q1	$178K	Sell	19,886 -11,844	-37%	-$81K	﹤0.01%	11524
2025 Q4	$174K	Sell	31,730 -23,108	-42%	-$119K	﹤0.01%	11160
2025 Q3	$219K	Buy	54,838 +46,727	+576%	+$196K	﹤0.01%	11076
2025 Q2	$21.9K	Buy	8,111 +1,510	+23%	+$4K	﹤0.01%	12085
2025 Q1	$34.6K	Buy	+6,601	New	+$41.7K	﹤0.01%	12680
2024 Q3	–	Sell	-35,000	Closed	-$375K	–	15081
2024 Q2	$375K	Sell	35,000 -14,958	-30%	-$203K	﹤0.01%	8649
2024 Q1	$739K	Buy	49,958 +10,150	+25%	+$141K	﹤0.01%	7549
2023 Q4	$761K	Buy	39,808 +4,563	+13%	+$112K	﹤0.01%	7229
2023 Q3	$950K	Sell	35,245 -1,676	-5%	-$72.6K	﹤0.01%	6659
2023 Q2	$1.67M	Sell	36,921 -7,244	-16%	-$355K	﹤0.01%	5479
2023 Q1	$2.02M	Sell	44,165 -7	-0%	-$362	﹤0.01%	5351
2022 Q4	$2.32M	Buy	+44,172	New	+$2.61M	﹤0.01%	5206

Other funds holding RLYB

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

Citadel Advisors's RLYB Position: Q2 2026 in Review

Citadel Advisors increased its Rallybio (RLYB) stake by 263% in Q2 2026, buying an estimated $673K and bringing the position to 72,200 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #7857.

Citadel Advisors first reported a position in RLYB in Q4 2022 and has held it in 13 quarters since. The position peaked at $2.32M in Q4 2022. 37 funds tracked by Wall St. Rank hold RLYB as of Q2 2026.

Citadel Advisors held 72,200 shares of Rallybio worth $1.16M as of Q2 2026.
Citadel Advisors bought 52,314 Rallybio shares in Q2 2026, an estimated $673K.
Rallybio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7857 holding.
Citadel Advisors first reported a position in Rallybio in Q4 2022 and has held it in 13 quarters since.
Citadel Advisors's Rallybio position peaked at $2.32M in Q4 2022.
37 funds tracked by Wall St. Rank held Rallybio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.